New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte's Genomic Tests in Interstitial Lung Disease and Lung Cancer
Copyright 2022, Business Wire.
news
2022-10-18 20:05:00

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that two abstracts highlighting the clinical value of the company's Envisia Genomic Classifier and Percepta Nasal Swab tests in interstitial lung disease (ILD) and lung cancer, respectively, were presented as posters today at the American College of Chest Physicians (CHEST) Annual Meeting 2022, taking place in Nashville, Tenn., October 16-19. The first poster provides further evidence that the Envisia Ge
